| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MUC5B |
| Uniprot No | Q9HC84 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 4186-4295aa |
| 氨基酸序列 | ELGQVVECSLDFGLVCRNREQVGKFKMCFNYEIRVFCCNYGHCPSTPATSSTAMPSSTPGTTWILTELTTTATTTASTGSTATPSSTPGTAPPPKVLTSPATTPTATSSK |
| 预测分子量 | 18.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MUC5B重组蛋白的3篇示例参考文献(注：内容为模拟概括，具体文献需通过学术数据库验证)：
---
1. **文献名称**: *"Recombinant Human MUC5B Mucin Forms Polymers with Distinct Rheological Properties"*
**作者**: Roy, M.G. et al.
**摘要**: 研究报道了重组MUC5B蛋白在体外的高效表达及纯化方法，发现其能自组装形成多聚体结构，并证实其糖基化模式影响黏液层的黏弹性，为呼吸道黏液屏障机制研究提供模型。
2. **文献名称**: *"Structural and Functional Characterization of Recombinant MUC5B in Airway Defense"*
**作者**: Burgess, J.D. et al.
**摘要**: 通过重组MUC5B蛋白的冷冻电镜分析，揭示了其N端结构域在聚合物形成中的关键作用，并证明其通过调控黏液水合状态参与病原体清除功能。
3. **文献名称**: *"MUC5B Overexpression via Recombinant Systems Links to Chronic Obstructive Pulmonary Disease"*
**作者**: Chen, Q. et al.
**摘要**: 利用重组MUC5B过表达细胞模型，发现其异常分泌可激活NF-κB通路，加剧气道炎症反应，提示其在COPD等疾病中的潜在治疗靶点价值。
---
**注意**：以上为基于领域知识的模拟摘要，实际文献需通过PubMed、Google Scholar等平台以“MUC5B recombinant protein”为关键词检索，并筛选近年高被引论文。
MUC5B, a member of the mucin family, is a high-molecular-weight glycoprotein critical for mucosal protection and lubrication in the human body. As a gel-forming mucin, it is secreted by specialized epithelial cells in tissues such as the respiratory tract, salivary glands, and cervix. Its primary function lies in forming viscoelastic mucus gels that trap pathogens, particles, and irritants, while facilitating their clearance via mechanical actions like coughing or ciliary movement. Structurally, MUC5B consists of a central protein backbone rich in serine, threonine, and proline residues (PTS domain), which undergoes extensive O-glycosylation, flanked by cysteine-rich terminal domains that enable polymerization. These features contribute to its gel-forming properties and resistance to proteolytic degradation.
Recombinant MUC5B protein refers to the genetically engineered version produced in vitro, often using mammalian expression systems (e.g., CHO cells) to preserve post-translational modifications. Its production addresses challenges in isolating native MUC5B from biological fluids, which is complicated by its large size (>500 kDa) and heterogeneity. Recombinant technology allows controlled study of domain-specific functions, glycosylation patterns, and molecular interactions. Research using recombinant MUC5B has advanced understanding of mucin overexpression in pathologies like chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis (IPF), where abnormal mucus contributes to disease progression. It also serves as a tool for drug delivery studies, biomaterial design, and investigating host-pathogen interactions. However, replicating its native glycosylation profile remains technically demanding, driving ongoing optimization of expression platforms. Current studies focus on leveraging recombinant MUC5B to develop mucolytic agents, mucin-targeted diagnostics, and synthetic mucus models for therapeutic testing.
×
